Actively Recruiting
Phase 2 Study Evaluating Safety and Effectiveness of Soquelitinib for Moderate to Severe Atopic Dermatitis
Led by Corvus Pharmaceuticals, Inc. · Updated on 2026-03-05
200
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how well different doses of soquelitinib work in adults with moderate to severe atopic dermatitis AD. This Phase 2 study compares soquelitinib with a placebo to understand its safety, tolerability, and preliminary effectiveness. The study focuses on tracking changes in participants skin condition and monitoring side effects to assess how well participants handle the treatment. Participants will take soquelitinib or placebo tablets twice daily for 12 weeks, with different groups receiving varying doses to maintain blinding. The study includes four groups three receiving different doses of soquelitinib and one receiving placebo. This treatment period is followed by scheduled clinic visits to monitor progress and safety. During the study, participants will visit the clinic weekly for the first two weeks, then every two weeks during treatment, and return for follow-up visits at 30, 60, and 90 days after the last dose. Researchers will assess changes in the Eczema Area and Severity Index EASI score, Investigator Global Assessment, and Peak Pruritus-Numerical Rating Scale. Safety and tolerability are monitored up to 30 days after treatment ends, with regular evaluations to track participants skin and overall health.
CONDITIONS
Brief Title
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
Research Team
C
Corvus Clinical Trials
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here